Pulmonary drug delivery system
April 19, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod and apparatus for administering dehydrated liposomes by inhalation Methods and compositions for the treatment of lung conditions Pulmonary administration of pharmaceutically active substances Method for administering pharmaceuticals, including liquid surfactant, to the lungs Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations Methods and apparatus for drug delivery using supercritical solutions Patent #: 5301664 InventorsAssigneeApplicationNo. 229600 filed on 04/19/1994US Classes:514/3, Insulin or derivative514/807, OXYTOXIN, VASOPRESSIN OR DERIVATIVES514/975CHARACTERIZED BY THE DESIGNATED SURFACTANT USEDExaminersPrimary: Rose, Shep K.Attorney, Agent or FirmInternational ClassesA61K 038/28A61K 038/11 A61K 045/08 AbstractThe present invention provides a method of improving the efficiency of absorption into the bloodstream of drugs delivered through the pulmonary route. The drug is mixed with surfactant, preferably a surfactant naturally produced by the lung. This method is found to enhance the absorption of pharmaceutical compositions, and in particular those comprising protein, eg insulin, or peptides, eg vasopressin.Other References
| |
